Paul Hudson, Sanofi CEO (Raphael Lafargue/Abaca/Sipa USA; Sipa via AP Images)

Sanofi keeps nip­ping at J&J's heels as Sar­clisa notch­es new FDA ap­proval in mul­ti­ple myelo­ma

The mul­ti­ple myelo­ma ri­val­ry be­tween Sanofi and J&J con­tin­ued Wednes­day evening, with the French drug­mak­er’s Sar­clisa tak­ing home a new ap­proval in the in­di­ca­tion.

US reg­u­la­tors OK’d the drug in com­bi­na­tion with Am­gen’s Kypro­lis and the steroid dex­am­etha­sone for adults with re­lapsed or re­frac­to­ry mul­ti­ple myelo­ma who have re­ceived be­tween one and three pre­vi­ous lines of treat­ment. It’s the sec­ond ap­proval for Sar­clisa, hav­ing pre­vi­ous­ly won a green light in March 2020 as a third-line treat­ment for the dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.